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Summary
The field of pathology is rapidly transforming from a semi-quantitative and empirical science toward
a Big-Data discipline. Large data-sets from across multiple –omics fields may now be extracted from
a patient’s tissue sample. Tissue is, however, complex, heterogeneous and prone to artefact. A
reductionist view of tissue and disease progression, which does not take this complexity into account,
may lead to single biomarkers failing in clinical trials. The integration of standardised multi-omics
Big-Data and the retention of valuable information on spatial heterogeneity is imperative to model
complex disease mechanisms. Mathematical modelling through systems pathology approaches is the
ideal medium to distil the significant information from these large, multi-parametric and hierarchical
data-sets. Systems pathology may also predict the dynamical response of disease progression or
response to therapy regimens from a static tissue sample. Next generation pathology will incorporate
Big-Data with systems medicine in order to personalise clinical practise for both prognostic and
predictive patient care.
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1. Introduction
The manual, microscopic viewing of thinly cut and stained tissue sections by histopathologists has
been the steadfast method of deciphering tissue architecture and concluding a prognosis for multiple
diseases for over one hundred years. The field of pathology recognises the rich data source which lies
within a tissue section. With the aid of specific histochemical stains, augmented by immunological
and even mRNA or DNA based approaches, the pathologist takes into account the entire
heterogeneous and heterotypic microenvironment and its interactions across the tissue section.
Through experience they are able to process this complex, sometimes subtle information, and translate
it in order to aid their diagnostic or prognostic conclusion. Research pathologists also apply this
methodology to evaluate novel or significant prognostic features such as the tumour differentiation,
tumour gland morphology at the invasive front or immune infiltrate within the microenvironment. The
development of immunohistochemistry from the 1940s provided the pathologist with the ability to
interrogate the tissue section with a further level of complexity where they could match biomarker
expression with histopathological features and morphometry, although it took some time and the
advent of monoclonal antibodies some 30 years or so later for a dramatic increase in routine use of the
technology. The use of protein biomarkers, visualised through immunohistochemistry, allowed
quantification at both spatial heterogeneity and subcellular resolution. Since the post-omics era the
field of modern pathology is experiencing an explosion of data across multiple but disparate –omics
strands. Most notably within the clinic is the genomic profiling of a patient’s tissue sample through
next generation sequencing (NGS) where, in colorectal cancer for example, EGFR and KRAS
mutations now may be routinely tested for in order to predict the response to anti-EGFR antibody
treatment. Single “magic-bullet” biomarkers, however, have a limited use in clinical prognosis, drug
prediction and efficacy studies as they attempt to describe or modulate complex multi-pathway
molecular and cellular interactions in an often too simplistic way.
Advances in the integration of genomics, proteomics, transcriptomics, epigenomics and the emerging
field of image analysis based phenomics are now able to add valuable information to the hierarchical
understanding of complex disease mechanisms. These molecular signatures correlated with
morphological and clinical data have the ability to advance traditional diagnostic medicine from broad
population-based prediction to a more personalised and precision based science. Pathology has
overcome the bottleneck of creating large, hierarchical and complex “Big-Data”, however the
challenge the field is now facing is how to handle this data in a meaningful manner which directly
leads to translational impact. The over-arching goal of modern big-data pathology is to infer a
dynamical prediction of disease from a static patient tissue sample. Systems pathology through
mathematical modelling allows the integration, interrogation and identification of significant
parameters from large multi-omics data sets while having the ability to add a dynamic aspect to
personalised medicine.
2. Tissue is Heterogeneous
Tissue is extremely heterogeneous and cancer especially so; cancer heterogeneity can originate from
multiple sources: cell of origin, clonal evolution, cancer stem cells (CSC), response to
microenvironment and host factors as well as stromal or immune cell infiltrate. The clonal evolution
theory states that the cancers build up heterogeneous subpopulations after concurrent mutations over
multiple rounds of cell division due to the plasticity of the cells through chromosomal and replicative
instability or exogenous insults. These heterogeneous subpopulations are under the influence of
natural selection where they may acquire mutations which ultimately lead to cell death while others
accumulate a specific set of driver mutations allowing the cancer cells to metastasise. CSCs may
originate from healthy tissue stem cells or may have attained their stem-like phenotype through
epigenetic alterations of the genome or through stromal cell interaction from their
microenvironmental niche. The stem-like attributes associated with CSCs would confer a certain
amount of plasticity upon it in order for it to evade aggressive treatment regimens or commit to the
metastatic cascade. CSCs may have the ability to produce hierarchical heterogeneous cell
subpopulation progenies of which only some are tumourigenic and others differentiated. CSCs are
thought to initiate tumourigenesis, have the ability to propagate the cancer after chemotherapy and a
cure for the patient depends on the eradication of such self-renewing cells. CSCs also appear to be
more resistant to radiation and chemotherapeutic treatment and may incur tumour recurrence even
after a long period of remission and dormancy. More recently the “Big Bang model” of intra-tumour
heterogeneity has been described where tumours mainly grow as a single expansion and that intra-
tumour heterogeneity within tumour subpopulations is high but occurs early on in the tumour’s
evolution. In this model aggressive subclones may not be predominant and can remain undetected
although they would provide overall resistance to subsequent insult by treatment regimens (1).
The focus of cancer research for prognosis, prediction and drug discovery has been on the tumour
itself however this target is changing. It is becoming apparent that the tumour microenvironment as a
whole, and more precisely the stromal and immune infiltrate, is increasingly important in tumour
progression and evasion of chemotherapy. The host interaction on the tumour, their stem-cell
subpopulations and their microenvironmental niche adds a further level of heterogeneity to the
tumour. Spatial heterogeneity within the stromal compartment of the tumour is a critical influence on
the tumour, its subsequent progression and potential resistance to therapy. The combination of the
above creates a further level of complexity in the accurate understanding of disease and for its
dynamic modelling.
3. Tissue samples are imperfect
A wealth of prognostic and predictive information lies within the patient’s tissue sample. Classical
histopathology strives to infer dynamical prediction of disease progression from the static artefact
which is the tissue section. The pathologist directly observes microscopically the complex diseased
tissue and its interaction with the host microenvironment in order to mentally compute these multiple
signals into a prognosis. This has long been the gold standard in clinical prognosis. Although multiple
novel prognostic methodologies for Colorectal Cancer (CRC) have been developed to replace or
augment classical pathology, and while some show promise, for example the gene expression
signatures ColoPrint (2) and Oncotype DX (3), none has established itself within routine clinical
prognosis. The classical Dukes and TNM morphological and histological staging of the disease
remains steadfast in clinical pathology. One reason for this is standardisation and the imperfection of
tissue. The human eye can account for the variation and artefacts that occur between surgical removal
of the tissue through to mounting sections onto microscope slides for analysis. Poor and small sample
size, imperfection and damage to tissue as well as poor tissue orientation can be easily disregarded by
the pathologist while they can glean the pertinent information from the final stained tissue section.
Automated quantification of the tissue section, spanning the -omics fields, is not able to be so
selective and may therefore return variable results. The need for standardisation across all aspects of
automated tissue datafication is therefore essential.
Advances in extracting data in a meaningful and robust manner will add value to classical
histopathology methodologies and provide greater impact and accuracy of patient stratification at a
more personalized level than current population statistics, such as TNM staging. This is increasingly
relevant when the quantification techniques take into account the heterogeneity of the disease and
report on it. Datafication of tissue is the extraction of information in a fully quantifiable and
standardised manner. This can take the form of quantifying a single biomarker to capturing a complex
and hierarchical multi-modal omics signature. Routinely, single read-outs are extracted from a single
tissue sample however advances in data capturing technologies now allow multiple readouts captured
across multiple –omics fields which may be reported across distinct subpopulations identified through
morphometric or biomarker expression. Big-data pathology is now a reality but creating standardized
data sets amenable to complex modelling and which take into account the imperfection of tissue and
its inherent heterogeneity is still in its infancy.
4. Quantifying heterogeneity
Understanding tumour heterogeneity is important in striving toward an intelligent and individualised
treatment strategy which translates into clinical impact. To truly fulfil a personalised medicine
approach and select the correct combination therapy for a patient it is essential to know which
mutational or epigenetic aberrations their cancer carries in both primary and distant disease and what
the subsequent phenotypic and functional effect on the cells and their microenvironment are.
Multiple interactions at multiple levels occur in tissue architecture. Histopathology describes the end
result but not the underlying molecular mechanisms. Since the post ‘omics’ era scientists have been
armed with a suite of new tools to identify biomarkers to subgroup a patient’s cancer at the molecular
level. Using these tools a raft of data and new biomarkers have been discovered over the last few
decades and allowed genome scale analysis and comparisons. The main disciplines to bear the wealth
of the results are genomics, transcriptomics, proteomics and epi-genetics. Technologies such as NGS
and arrayCGH allow the mutation and copy number status of the genome to be analysed. RNA
microarray chips and RNA-sequencing technologies are employed to profile gene expression whereas
Reverse phase protein array (RPPA) and mass spectrometry have brought proteomics into the field of
Big-Data pathology.
Inter-patient and intra-patient heterogeneity exists (Figure 1) and the aim of all ‘omics’ research is to
identify biomarkers which can lead to targeted drug discovery programmes or companion diagnostics
which will allow the clinician and pathologist to make rapid informed decisions on the prognosis of
the disease and to predict which treatment will display the greatest efficacy and best outcome as
possible for the individual patient.
Although the above methodologies to quantify the molecular mode of action driving cancer subtypes
have added significant value, they also hold disadvantages to assaying such complex material. To
extract DNA, RNA and protein molecules these assays usually homogenise and destroy the tissue
integrity. The tissue is literally “mashed and measured” mixing together any subpopulations of cancer
and host cells expressing differential properties while losing spatial resolution. This results in one
end-point being reported for the whole tumour. Due to the nature of these applications, intra-tumoural
heterogeneity of the tissue may be under-detected where the dominant or most abundant genotypes or
phenotypes mask signal from smaller cell populations within the tumour. Healthy tissue and host cells
from the tumour microenvironment are both also added to the molecular sample creating a further
source of noise to the signal and could increase the reporting of false positive or negative results.
Under-detection of tissue heterogeneity therefore leads to an urgent and difficult problem when
treating a patient with combination therapy, as resistant subgroups could go unnoticed and untreated.
There are, however, tools to overcome this problem which attempt to better quantify, and thus
comprehend, the complexity of heterogeneous tumours. One such tool is laser capture microdissection
(LCM) which isolates and analyses cells and sections of the tissue of interest, usually those displaying
morphological differences. This technique allows the separate analysis of distinct subpopulations as
well as comparing the tumour’s core, invasive edge and the stromal microenvironment. From these
distinct sections DNA, RNA and protein can be isolated and studied resulting in a cleaner profile of
the difference between regions of interest and their heterogeneity. Recent technological advances
allow molecular genomic and proteomic profiling with small sample sizes amenable to ever smaller
tissue samples which is advantageous in the study of heterogeneity. Background signals from
complex tissue can still create noise in these assays and robust and sensitive data depends on the LCM
technique as well as the specificity of probes, antibodies and detection technology used. To avoid
contamination of signals, from heterogeneous subpopulations within tissue, in situ imaging of protein
through Immunohistochemistry (IHC) and genomics through fluorescence in situ hybridisation
(FISH), may be applied. This has advantages over destructive assays as the tissue structure, spatial
orientation and sub-localisation of molecules are retained and heterogeneity can be visualised,
compartmentalised and quantified while providing insight into cellular interactions within the tumour
and its microenvironment. IHC further allows the visualisation of morphological status of the cells
expressing the biomarker of interest and allows the observer to correlate morphometric and proteomic
signatures at the cellular resolution. Spatial heterogeneity impacts the prognostic and predictive
significance of biomarkers and it is becoming increasingly apparent that this must be taken into
consideration for the modelling of disease. The immunoscore in colorectal cancer, which quantifies
the density and intra-tumoural location of CD3+ and CD8+ lymphocytes through image analysis, has
been shown to hold a higher prognostic significance than the gold standard of TNM staging
(4).Similarly, the spatial heterogeneity of unbiased and automatically quantified lymphocytes in breast
cancer tissue sections was statistically modelled and found to be associated to patient survival(5). In
the field of transcriptomics it has recently been discovered that mesenchymal cell gene expression
classifiers are linked to poor prognosis in colorectal cancer though it proves difficult to ascertain
whether these classifiers are expressed by the tumour or the stromal cells however
immunohistochemistry for mesenchymal proteins in tissue sections as well as laser capture
microdissection have elucidated that the mesenchymal signatures originate from stromal cancer-
associated fibroblasts and not from the tumour itself (6, 7).
Although the field of high content analysis is not new, where multiple parameters and biomarkers are
measured from fluorescently labelled cells(8), the discipline has been slow to translate to
histopathology and the clinic. This has been in part due to the complexity of tissue and its
imperfection compared to in vitro cell studies and the need for extensive validation and
standardisation for clinical use. This is now changing and digital pathology as well as automated
image analysis for tissue-based studies is rapidly emerging into the realm of clinical research. The
integration of digital pathology with automated image analysis brings advantages to the field. These
include the standardisation of quantification where observer variability is excluded and the robust
analysis of rare or complex features is captured. Traditionally image analysis in histopathology
concentrated on the quantification of protein expression through immunohistochemistry and
immunofluorescence (IF). This was to overcome the subjective manual and semi-quantitative scoring
of a 1+, 2+, 3+ system. Upon employing IF, image analysis software can perform fully quantified
continuous data-exports from which cut-offs can be calculated in order to stratify patient subgroups.
Computer based quantification of nuclear morphometry, however, has been practiced for over a
decade. Continuous improvements to image analysis software now allow the simultaneous export of
morphometric parameters of cells and histopathological features alongside biomarker quantification
associated to this feature. In this co-registering methodology it is possible to identify surrogate
morphological features which correlate with molecular phenotype.
The market leading tissue imaging platform manufacturers provide their own image analysis solutions
for chromogenic and fluorescence assays which allows segmentation of cells and subcellular
compartments and subsequent biomarker quantification within heterogeneous tissue. These software
packages are designed to work in connection with the images captured from their own platforms and
can sometimes be restrictive to the quantification of set assays, biomarkers and parameters. Definiens
(http://www.definiens.com/), Indica lab (http://indicalab.com/) and Visiopharm
(http://www.visiopharm.com/) offer image analysis packages which can import images from most
microscopes and allow a more flexible image analysis environment to capture the complexity of the
heterogeneous tissue section.
While the imaging of a single biomarker can yield predictive or prognostic information the ability to
multi-plex two or more markers on a single tissue section becomes a much more powerful tool. An
advantage of IF based image analysis is the ability to multiplex, co-register and quantify biomarkers
at the cellular resolution. Multi-plexing reports on protein interactions, pathway activation and
multiple cellular events. Accurate co-localisation and spatial resolution of multiple biomarkers or
histological features on the same section of tissue reports a richer high content and functional data
than serial sections of one biomarker while saving the precious resource which is the tissue sample.
Researchers can quantify multiple proteins on a per cell basis or accurately quantify multiple cell
types within a heterogeneous population. Traditional multiplexing is limited by bleed through of
fluorophores and chromagens as well as antibody cross-reactivity of secondary host-species. Multi-
spectral imaging and un-mixing of chromagens and fluorophores allows an accurate spectral readout
for each biomarker of interest, increases the multi-plexing capacity and negates any autofluorescence.
Sophisticated image analysis software and multi-plexed in situ labelling permit the big-data capture
from image analysis based segmented tissue sections to quantify the data-rich histopathology and the
interactions and spatial heterogeneity of the cancer microenvironment’s phenotypic features. This
involves the extraction of complex and hierarchical data pertaining to a single segmented feature or
set of features across the segmented tissue section. This data may be captured through co-registering
of biomarkers as proteomic or genomic signals, as multiple morphometric and texture parameters or a
combination of both; essentially extracting as much data as possible from each single segmented
object within the image. A multi-parametric signature is therefore built up for each tissue sample
which may be compiled of multi-omic image based features. Tissue subpopulations may be identified
in this manner and further mined through in situ labelling or microdissection to interrogate the
patient’s sample at the personalised level for predictive or prognostic pathology (Figure 2).
Sophisticated data mining is required to identify the significant single or combination of parameters
within the signature in order to stratify patients for prognostic or predictive purposes. Data mining
techniques previously applied to identify significant parameters have been logistic regression analysis
and ensemble decision tree models. Further advancements in in situ labelling and image analysis such
as mass spectrometry imaging, Next-generation immunohistochemistry (9) and multi-parametric data
capture, where biomarkers are correlated to morphometry, are catapulting this field into the realm of
true Big-Data alongside the more traditional –omics fields. Image analysis and in situ labelling of
tissue sections coupled to spatial statistics will most probably factor highly when profiling a diseases
complex heterogeneous microenvironment in the future of systems pathology.
5. Integrative pathology
Traditional omics research attempts to identify single molecular or histopathological features which
could be utilized for prognosis or prediction of response to drug therapy. Cancer is, however, a very
complex disease with multiple molecular interactions within the cell and multiple cellular interactions
within the microenvironment. Many single biomarkers never translate to the clinic, as they do not take
into account the complexity and heterogeneity of the disease. Integrating large scale data from
multiple omics fields may help to address this problem as it will create a better understanding of the
multiple molecular interactions occurring within the cell and how these translate to disease
progression. This approach was exemplified in colorectal cancer where histopathological subtypes
were integrated with methylation and mutation status to assess their correlation and impact on
prognosis (10). Integrative large scale pathology has also been implemented in breast cancer where
cellular resolution of in situ and co-registered genotype and phenotype was utilised to study intra-
tumoural heterogeneity between primary and distant metastasis for studies of prognosis and potential
drug targets (11). Finally, a further breast cancer study integrated a multi-omics signature and
discovered JAK-STAT and TNF signalling pathways to be significant in triple negative disease which
could lead to novel and personalised drug treatments (12). There is a wealth of data collected during
classical histopathology which largely remains unused in clinical decision making. This clinical data
is beginning to be integrated with the modern datafication modalities as a further hierarchical level of
understanding of the disease from the tissue. In mucoepidermoid carcinoma; histopathology,
immunophenotypic and cytogenetic parameters were integrated to identify a signature which was able
to identify the pulmonary disease from other subtypes of lung cancer (13). Clinical and molecular data
is now also being integrated with the complex and data-rich image-based phenotypic signatures to
investigate cancer heterogeneity and its interaction with the microenvironment. The morphometric
signatures can also be correlated to the genomic profile and clinical outcome (5). Computational IT
solutions are also now available which allow the incorporation of multiscale omics data (14, 15) as
well as integrate it with clinical information (16).
6. Systems pathology
Pathology is now adept at creating large and complex data sources from across the omics fields and
more recently including histopathology, morphometrics and spatial heterogeneity. This data, however,
must be integrated in a meaningful way which makes best use of its complexity, is standardized,
reproducible and robust enough to be clinically relevant. The challenge ahead is how to incorporate
this integrated data into models which can identify the optimal combinations of parameters to answer
clinical questions in a robust and standardised manner. Systems medicine, and more recently systems
pathology, takes a holistic view of tissue, the cell and its multitude of interactions. Systems pathology
requires a large amount of high-quality multi-scale data to be extracted from tissue and which acts as
input for predictive mathematical models. Although systems pathology has predominantly
concentrated on molecular profiling of the genome, transcriptome or proteome, image analysis based
multi-parametric biomarker and morphometry is perfectly matched to add to the hierarchical data
within a systems model. This additional in situ information allows the retention of the valuable spatial
heterogeneity within the diseases microenvironment.
Essentially, a modern integrative pathology would adopt the principles of 4P medicine in a systems
pathology approach. 4P medicine consists of Prediction, Personalisation, Prevention and Patient
participation (17). There are many definitions of systems medicine. Within Europe systems medicine
is defined by the EU consortium CASyM (www.casym.eu), as stated within the first chapter of this
book.
The principle of systems pathology is to predict a dynamic pathological response from static data sets.
The more standardised and robust the data which is used for input into the model directly relates to
the quality of prediction within the model. Systems pathology is complex with the implementation of
multiple differential equations into a multiscale dynamic model to predict a drug effect on a patient or
inform how that patient will respond over time. Systems pathology, under this definition, was utilised
to confirm the role of PTEN in Trastuzumab drug resistance (18). Systems pathology can also be
implemented to track tumour evolution post chemotherapy through intra-tumour heterogeneity and
spatial distribution of phenotype and genotype at the cellular level (19). In CRC a systems pathology
approach was employed to identify a disease recurrence signature in early stage patients from a multi-
omics data set where parameters associated with immune response were found to be the most
significant predictors (20).
Systems pathology is therefore already making a valuable impact into the field of translatable clinical
research. Systems pathology is the ideal tool to distill significant parameters with significant
population cut-offs, and which are therefore translatable to the clinic, from multiple integrated
complex Big-Data sets. This is what we have termed ‘Next Generation Pathology’. The ultimate goal
of next generation pathology is to make use of this hierarchical data captured across multiple
modalities from an imperfect and static tissue sample, in order to better understand both disease
progression and a patient’s personalised response to treatment.
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Figure captions
Figure 1. Inter- and Intra-patient heterogeneity
A) Loss of E-Cadherin at the invasive front of CRC. A TMA core taken from the invasive front of a
CRC patient tumour block. Neoplastic glands are visualized with antibody against panCK (green)
and counterstained with DAPI (blue). E-Cadherin (red) is not expressed in neoplastic glands at
the edge of the cancer invasion (green box) but is expressed in well differentiated glands located
closer to the tumour centre (red box).
B) Cytokeratin 7 inter-patient heterogeneity. TMA cores taken from 2 different patient blocks: core
A and core B. Core B shows high expression Cytokeratin 7 (red) in the neoplastic cells (green)
and Core A shows no Cytokeratin 7 expression.
Figure 2. Subpopulation segmentation and biomarker quantification through image analysis
Tumour subpopulation segmentation and classification through whole slide image analysis of
immunofluorescence labelled colorectal cancer tissue utilizing Definiens image analysis software. A)
raw image: DAPI (blue) and panCK (green). B) Image analysis algorithm automatically segments
tumour from stroma. C) Tissue is further segmented into stromal cells, tumour buds, poorly
differentiated clusters (PDC) and three tumour gland subpopulations. Ki67 (red) proliferation marker
is quantified within separate subpopulations at the invasive front (F & G) and the the tumour core (D
& E).
